(Q38865366)

7 September 2017

1 reference

title

Dementia in Down's syndrome (English)

1 reference

7 September 2017

1 reference

Gareth Williams

4

0 references

Clive Ballard

object named as

Clive Ballard

series ordinal

1

0 references

John Anthony Hardy

series ordinal

3

object named as

John Hardy

1 reference

7 September 2017

William Mobley

2

1 reference

PubMed ID

27302127

7 September 2017

Anne Corbett

series ordinal

5

1 reference

7 September 2017

11 April 2016

1 reference

7 September 2017

1 reference

7 September 2017

15

1 reference

7 September 2017

6

1 reference

7 September 2017

622-636

1 reference

Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Demographic characteristics, health conditions, and residential service use in adults with Down syndrome in 25 U.S. states.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Dementia and mortality in persons with Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Dementia in people with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Incidence and course of dementia in people with Down's syndrome: findings from a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A four year prospective study of age-related cognitive change in adults with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Cognitive impairment in adults with Down's syndrome: similarities to early cognitive changes in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The natural history of dementia in Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A prospective study of Alzheimer disease in Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Atypical aging in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Cognitive decline in Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A Pilot Study Examining Associations between DYRK1A and a-Synuclein Dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Effects of increasing task load on memory impairment in adults with Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Down syndrome, Alzheimer's disease and seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Down Syndrome and Attention-Deficit/Hyperactivity Disorder (ADHD)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

An experimental approach to detecting dementia in Down syndrome: a paradigm for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Some morphometric observations on the brains of patients with Down's syndrome: their relationship to age and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Neuroimaging of individuals with Down’s syndrome at-risk for dementia: Evidence for possible compensatory events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Biomarker modeling of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Parallel Compensatory and Pathological Events Associated with Tau Pathology in Middle Aged Individuals with Down Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Plasma ß-amyloid and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

1 reference

7 January 2021

Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Down's syndrome: Is there a decreased population of neurons?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The sequence of human chromosome 21 and implications for research into Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Phenotype associated with APP duplication in five families.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Mouse models of cognitive disorders in trisomy 21: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Expression of APP pathway mRNAs and proteins in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Polymorphic tetranucleotide repeat site within intron 7 of the beta-amyloid precursor protein gene and its lack of association with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Influence of the amyloid precursor protein locus on dementia in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Regulation and expression of the Alzheimer's beta/A4 amyloid protein precursor in health, disease, and Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Positive and negative regulation of APP amyloidogenesis by sumoylation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Sorting nexin 27 regulates Aβ production through modulating γ-secretase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Lack of association between the polymorphisms of beta-site APP-cleaving enzyme 2 (BACE2) 5'-flanking region and sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The role of DYRK1A in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Interplay of Cu,Zn superoxide dismutase and nitric oxide synthase in neurodegenerative processes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Defective mitochondrial function in vivo in skeletal muscle in adults with Down's syndrome: a 31P-MRS study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Mitochondrial retrograde signaling regulates neuronal function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Molecular mechanisms of cellular cholesterol efflux

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

New insights into the therapeutic potential of Girk channels.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

A searchable cross-platform gene expression database reveals connections between drug treatments and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Regional and cellular gene expression changes in human Huntington's disease brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The microtubule associated protein Tau gene and Alzheimer's disease--an association study and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The Extended Tau Haplotype and the Age of Onset of Dementia in Down Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The Role of PICALM in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Association between genetic variants in sortilin-related receptor 1 (SORL1) and Alzheimer's disease in adults with Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Interactive effects of physical activity and APOE-ε4 on BOLD semantic memory activation in healthy elders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Minocycline prevents cholinergic loss in a mouse model of Down's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Prospects for Improving Brain Function in Individuals with Down Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Seizures associated with fluoxetine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Human neural progenitor cell engraftment increases neurogenesis and microglial recruitment in the brain of rats with stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The use of mouse models to understand and improve cognitive deficits in Down syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Nerve growth factor metabolic dysfunction in Down's syndrome brains.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Norepinephrine Protects against Amyloid-β Toxicity via TrkB.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

Associations between cognitively stimulating leisure activities, cognitive function and age-related cognitive decline.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2816%2900063-6

7 January 2021

10.1016/S1474-4422(16)00063-6

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27302127